AKI - Acute Kidney InjuryNCT06596785
Risk Factors and Deep Learning Model for CI-AKI
An observational study of AKI - Acute Kidney Injury, run by Xiao Li，MD at 1 site in China.
Trial summary
Contrast-associated acute kidney injury (CI-AKI) is a sudden and significant decline in renal function resulting from the use of a contrast agent. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- AKI - Acute Kidney Injury
- How many people
- 2,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2024to 1 Jun 2025
- How long will I take part?
- 1 Month
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: hospital
Who may be able to join
- patients who received iodinated contrast agents during hospitalization
- age ≥ 18 years
- hospitalization length ≥ 48 hours
- at least two serum creatinine tests during hospitalization
Who cannot join
- patients with stage 4 or 5 chronic kidney disease prior to admission
- patients undergoing hemodialysis, hemofiltration or peritoneal before admission
- a history of nephrectomy or kidney transplantation during hospitalization
- incomplete clinical information
- Serum creatinine always ≤ 40 μmol/L during hospitalization
Trial locations and contacts
1 site in 1 country.
China1 site
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, 250014
About this study
Official title: Investigation and Early Risk Prediction of Acute Kidney Injury Caused by Iodinated Contrast Agents: Development of CI-AKIDPi Model Based on Interpretable Deep Learning
Contrast-associated acute kidney injury (CI-AKI) is a sudden and significant decline in renal function resulting from the use of a contrast agent.
Read the detailed description
Contrast-associated acute kidney injury (CI-AKI) is a sudden and significant decline in renal function resulting from the use of a contrast agent. Despite the frequent use of iodinated contrast agents in medical investigations, predictive models for CI-AKI are scarce. This study aimed to construct and validate interpretable deep learning models for the early risk prediction of acute kidney injury (AKI) associated with iodinated contrast agents.
- Conditions
- AKI - Acute Kidney Injury
- Medical subject headings
- Acute Kidney Injury
What is being measured
The primary outcome is the main question the study is designed to answer.
AKI
During the patient's hospitalization, acute kidney injury occurred after the use of Iodinated contrast media
Measured: Completed through study, up to half a year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start1 Jun 2024
- Primary completion1 Mar 2025 (estimated)
- Study completion1 Jun 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AKI - Acute Kidney InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (actual)
- Target duration
- 1 Month
Sponsor and investigators
- Lead sponsor
- Xiao Li，MD
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Xiao Li，MD, Qianfoshan Hospital
- Investigators
- Xiao Lii, Principal investigator, Qianfoshan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06596785
- Sponsor's protocol ID
- LCYX-LX-20240101
- Status last verified
- Sep 2024
- First submitted
- 8 Sep 2024
- Last updated
- 19 Sep 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation and Early Risk Prediction of Acute Kidney Injury Caused by Iodinated Contrast Agents: Development of CI-AKIDPi Model Based on Interpretable Deep Learning
- ClinicalTrials.gov ID
- NCT06596785
- Acronym / sponsor ID
- LCYX-LX-20240101
- Conditions
- AKI - Acute Kidney Injury
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 2,000 participants (actual)
- Lead sponsor
- Xiao Li，MDUniversity, hospital or other
- Study start
- 1 Jun 2024 (actual)
- Primary completion
- 1 Mar 2025 (estimated)
- Study completion
- 1 Jun 2025 (estimated)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Contrast-associated acute kidney injury (CI-AKI) is a sudden and significant decline in renal function resulting from the use of a contrast agent.
Detailed description
Contrast-associated acute kidney injury (CI-AKI) is a sudden and significant decline in renal function resulting from the use of a contrast agent. Despite the frequent use of iodinated contrast agents in medical investigations, predictive models for CI-AKI are scarce. This study aimed to construct and validate interpretable deep learning models for the early risk prediction of acute kidney injury (AKI) associated with iodinated contrast agents.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 1 Month
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- hospital
Key inclusion criteria (4 listed)
- patients who received iodinated contrast agents during hospitalization
- age ≥ 18 years
- hospitalization length ≥ 48 hours
- at least two serum creatinine tests during hospitalization
Key exclusion criteria (5 listed)
- patients with stage 4 or 5 chronic kidney disease prior to admission
- patients undergoing hemodialysis, hemofiltration or peritoneal before admission
- a history of nephrectomy or kidney transplantation during hospitalization
- incomplete clinical information
- Serum creatinine always ≤ 40 μmol/L during hospitalization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
AKI
Time frame: Completed through study, up to half a year
During the patient's hospitalization, acute kidney injury occurred after the use of Iodinated contrast media
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Sep 2024.
Related trials for AKI - Acute Kidney Injury
RecruitingPhase 4
Effect of a Furosemide Stress Test-Guided Strategy on Liberation From Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury
Acute Kidney Injury
Not yet recruitingObservational study
Effect of Filter Lifespan in CRRT on New Infections in Critically Ill Patients With AKI
Acute Kidney Injury
Enrolling by invitationObservational study
ProNephro NGAL Test for Early Detection of Acute Kidney Injury in Adult ICU Patients (ALPACA)
Acute Kidney Injury
Recruiting
LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)
Acute Kidney Injury, Dialysis; Complications
Not yet recruiting
Hemodynamic Resuscitation Guided by Non-Invasive Mean Systemic Filling Pressure to Prevent Acute Kidney Injury in Septic Shock
Acute Kidney Injury Due to Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xiao Lii principal investigator
Qianfoshan Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of AKI - Acute Kidney Injury, run by Xiao Li，MD at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AKI (time frame: Completed through study, up to half a year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2024.